Table 2 The relationship between the grade of CIL and overall survival (OS)
Characteristics | Number(n,%) | Events(n,%) | II/III vs. 0/I | II/III vs. IV | IV vs. 0/I | |||
|---|---|---|---|---|---|---|---|---|
HR, 95%CI | P-value | HR, 95%CI | P-value | HR, 95%CI | P-value | |||
Menstrual status | ||||||||
Premenstrual | 280(63.3) | 14(3.2) | 0.206[0.068,0.617] | 0.005 | 3.417[0.420,27.770] | 0.250 | 0.060[0.007,0.502] | 0.009 |
Postmenstrual | 162(36.7) | 17(3.8) | 2.023[0.263,15.559] | 0.499 | 1.837[0.592,5.696] | 0.292 | 1.101[0.123,9.854] | 0.931 |
Clinical stagea | ||||||||
I/II | 289(65.4) | 14(3.2) | 0.881[0.195,3.977] | 0.869 | 5.385[0.695,41.710] | 0.107 | 0.164[0.015,1.805] | 0.139 |
III | 153(34.6) | 17(3.8) | 0.288[0.094,0.884] | 0.030 | 1.240[0.373,4.117] | 0.726 | 0.232[0.062,0.868] | 0.030 |
Molecular type | ||||||||
HR+ | 280(63.3) | 24(5.4) | 0.466[0.189,1.149] | 0.097 | 4.439[1.015,19.413] | 0.048 | 0.105[0.022,0.507] | 0.005 |
HER2+ | 182(41.2) | 12(2.7) | 0.167[0.044,0.631] | 0.008 | 0.914[0.218,3.828] | 0.902 | 0.182[0.040,0.831] | 0.028 |
TN | 83(18.8) | 5(1.1) | NA | 0.999 | 0.756[0.126,4.525] | 0.759 | NA | 0.999 |
N stage | ||||||||
N2/N3 | 151(34.2) | 17(3.8) | 0.292[0.095,0.896] | 0.031 | 1.243[0.374,4.127] | 0.723 | 0.235[0.063,0.878] | 0.031 |
N0/N1 | 291(65.8) | 14(3.2) | 0.876[0.194,3.953] | 0.863 | 5.374[0.694,41.624] | 0.107 | 0.163[0.015,1.797] | 0.139 |
T stage | ||||||||
T3 | 29(6.6) | 4(0.9) | 0.073[0.007,0.819] | 0.034 | 0.204[0.012,3.344] | 0.265 | 0.360[0.032,4.000] | 0.405 |
T2 | 261(59.0) | 17(3.8) | 0.729[0.206,2.584] | 0.625 | 2.875[0.644,12.850] | 0.167 | 0.254[0.042,1.518] | 0.133 |
T1 | 152(34.4) | 10(2.3) | 0.516[0.099,2.680] | 0.431 | 2.269[0.456,11.289] | 0.317 | 0.227[0.031,1.647] | 0.143 |